Provided are a bispecific antibody, an encoding nucleic acid thereof, an AAV virus vector containing the nucleic acid, and a virus particle. Further provided is a pharmaceutical composition containing the bispecific antibody, the encoding nucleic acid, the AAV virus vector, or the virus particle. The bispecific antibody comprises binding domains specific to VEGF-A and ANG-2, and can be used for treating wet age-related macular degeneration or diabetic macular edema of a subject.

The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.

The present invention relates to a compound for use in a method for the modulation of movement of extracellular matrix (ECM) produced by mesothelial cells forming the surface of an internal organ, towards a site of injury of said organ of a subject suffering from or being at a risk of an injury of said organ. Additionally, the present invention relates to a compound for use in a particular in vivo screening method for identifying a modulator of movement of extracellular matrix (ECM) produced by mesothelial cells towards a site of injury of an internal organ of a subject. Further, the present invention relates to a specific in vitro screening method for identifying a modulator of the movement of ECM towards an external stimulus in a single cell suspension derived from the mesothelium.

The present invention provides a porous hollow fiber membrane and methods of using the membrane to select an immune checkpoint inhibitor. The membrane can be used in animal models with an immune system and using a low-cost common mouse. The host immune system is unable to attack the cancer cells within the membrane and an animal study proves that the membrane system can be performed within animals.

A protein selected from the group consisting of Chrdl1, Fam3c, Fam3b and a fragment thereof, or a polynucleotide encoding therefor, for use in treating or reducing the risk of heart disease.

The present invention relates to zebrafish embryo and adult models constructed by inducing inflammation with carboxymethyllysine (CML), which causes glycation toxicity, and a method for screening anti-inflammatory agents using the same. The present invention provides a method for screening a novel anti-inflammatory agent using zebrafish in which embryonic death, acute cytokine storm, and neuro-paralysis has been induced, whereby inflammatory diseases can be prevented or treated in a more convenient and cost-effective manner.